Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...
The Motley Fool on MSN12d
Is Merck Stock a Buy?Understanding the investment thesis for Merck requires appreciating the importance of its blockbuster cancer drug, Keytruda, ...
Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...
On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...
Merck’s stock fell Thursday morning, despite the company beating profit and sales estimates for the third quarter.
Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback